Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Pfizer co-promotes Searle's Cox-2 inhibitor

Executive Summary

In the US, Pfizer and Monsanto division GD Searle will develop and co-promote Searle's Cox-2 inhibitors celecoxib (Phase III) as Celebrex, and its second-generation compound (Phase II), both under development for treating arthritis and pain.
Deal Industry
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Product or Technology Swap
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register